Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2026-01-18 @ 7:24 PM
Study NCT ID:
NCT01609556
Status:
COMPLETED
Last Update Posted:
2021-02-17
First Post:
2012-05-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
Sponsor:
ImmunoGen, Inc.
Organization: